471820 — Cellromax Science Co Cashflow Statement

0.000.00%

Last trade - 00:00

Consumer CyclicalsHighly SpeculativeMicro CapNeutral

Annual cashflow statement for Cellromax Science Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	PROSPECTUS	PROSPECTUS	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final
Net Income/Starting Line	3,984	4,732	4,499	3,817
Depreciation
Amortisation
Non-Cash Items	1,827	2,448	151	1,905
Unusual Items
Other Non-Cash Items
Changes in Working Capital	-2,245	-1,998	65.9	136
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Taxes Payable
Change in Other Liabilities
Net Change in Other Assets & Liabilities
Other Operating Cash Flow
Cash from Operating Activities	3,913	5,522	5,066	6,294
Capital Expenditures	-523	-131	-683	-2,754
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	-8,698	-5,545	-2,591	-13,688
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	-9,222	-5,676	-3,274	-16,441
Financing Cash Flow Items	20	—	-20	9,477
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	-41.2	-44.5	-122	9,280
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	-5,350	-198	1,670	-866